Lynch, Allen W.
Theodoris, Christina V. http://orcid.org/0000-0003-1658-1447
Long, Henry W. http://orcid.org/0000-0001-6849-6629
Brown, Myles http://orcid.org/0000-0002-8213-1658
Liu, X. Shirley http://orcid.org/0000-0003-4736-7339
Meyer, Clifford A. http://orcid.org/0000-0002-8321-2839
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U24CA237617, U24CA237617, U24CA237617)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32GM007748)
Article History
Received: 23 November 2021
Accepted: 26 July 2022
First Online: 6 September 2022
Competing interests
: M.B. is a consultant to and receives sponsored research support from Novartis. M.B. serves on the SAB of H3 Biomedicine, Kronos Bio and GV20 Oncotherapy. X.S.L. conducted the work while being on the faculty at the Dana Farber Cancer Institute and is currently a board member and CEO of GV20 Therapeutics. The remaining authors declare no competing interests.